Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Approval symbols : BHC save search
U.S. District Court Upholds Final Judgment for XIFAXAN(R) 550 mg That Prevents FDA Approval of Norwich’s Abbreviated New Drug Application Until 2029
Published: 2023-05-17 (Crawled : 22:00) - biospace.com/
BHC | $8.69 1.05% 0.0% 2.9M
|
Health Technology
|
| O: 1.0%
H: 40.79%
C: 22.86%
fda drug approval application
Bausch Health Responds to Norwich Pharmaceuticals Tentative FDA Approval for a 200 mg Rifaximin
Published: 2022-09-09 (Crawled : 21:00) - biospace.com/
BHC | $8.69 1.05% 0.0% 2.9M
|
Health Technology
|
| O: 0.15%
H: 14.61%
C: 10.28%
fda tentative health approval
APMA Grants Seal of Approval for JUBLIA® (efinaconazole) Topical Solution, 10%
Published: 2021-12-06 (Crawled : 13:00) - biospace.com/
BHC | $8.69 1.05% 0.0% 2.9M
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
approval granted grant
Bausch + Lomb and Clearside Biomedical Announce FDA Approval of XIPERE™ (triamcinolone acetonide injectable suspension) for Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis
Published: 2021-10-25 (Crawled : 11:00) - biospace.com/
BHC | $8.69 1.05% 0.0% 2.9M
|
Health Technology
|
| O: 0.28%
H: 1.95%
C: 0.9%
CLSD P | $1.29 -2.27% -2.33% 230K
|
Health Technology
|
| O: 3.49%
H: 8.51%
C: -0.89%
treatment fda ema fda approval approval macular xipere injection
Nicox’s Licensee Bausch + Lomb Receives Approval for VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% in the United Arab Emirates
Published: 2021-06-25 (Crawled : 06:00) - globenewswire.com
BHC | $8.69 1.05% 0.0% 2.9M
|
Health Technology
|
| O: 0.44%
H: 1.19%
C: 0.2%
license approval
Nicox’s Licensee Bausch + Lomb Launches VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% in Taiwan and Receives Approval in Qatar
Published: 2021-05-04 (Crawled : 06:00) - globenewswire.com
BHC | $8.69 1.05% 0.0% 2.9M
|
Health Technology
|
| O: -4.84%
H: 0.54%
C: -6.56%
license approval
BAUSCH HEALTH ANNOUNCES VYZULTA® (LATANOPROSTENE BUNOD OPHTHALMIC SOLUTION), 0.024%, IS NOW APPROVED IN BRAZIL
Published: 2021-04-16 (Crawled : 06:00) - globenewswire.com
BHC | $8.69 1.05% 0.0% 2.9M
|
Health Technology
|
| O: 0.3%
H: 0.36%
C: -1.18%
brazil approval health
FDA Approves Bausch + Lomb ClearVisc™ Dispersive Ophthalmic Viscosurgical Device
Published: 2021-04-07 (Crawled : 12:00) - prnewswire.com
BHC | $8.69 1.05% 0.0% 2.9M
|
Health Technology
|
| O: -0.1%
H: 1.33%
C: 1.09%
fda device approval fda approval
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.